title: Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.
abstract: OBJECTIVE
  To determine the safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution (Vigamox) in patients having cataract surgery.
  
  
  METHODS
  American Eye Center, Manila, Philippines.
  
  
  METHODS
  Preoperative and 1-month postoperative anterior chamber reaction, corneal endothelial cell density, and corneal thickness were assessed in 65 eyes that had cataract surgery with intracameral moxifloxacin. All eyes received 0.1 mL intracameral moxifloxacin 0.5% ophthalmic solution containing 500 mug of moxifloxacin as the last step of phacoemulsification. Different ophthalmologists conducted the postoperative evaluation in an observer-masked fashion. A P value less than 0.05 was considered significant.
  
  
  RESULTS
  All 65 eyes completed the study. The mean age was 69.5 years +/- 9.13 (SD) (range 48 to 84 years). All eyes had a postoperative best corrected visual acuity of 20/30 or better. All eyes had trace to +2 cells and flare anterior chamber reaction only on the first day after surgery. The mean endothelial cell count was 2491.52 cells/mm(2) preoperatively and 2421.58 cells/mm(2) postoperatively. The mean difference was 70 cells/mm(2), which not statistically significant (P = .737). The increase of 17.80 microm in postoperative pachymetry 1 month after surgery was not statistically significant (P>.65).
  
  
  CONCLUSIONS
  Intracameral Vigamox 0.5 mg/mL appeared to be nontoxic in terms of visual rehabilitation, anterior chamber reaction, pachymetry, and corneal endothelial cell density.
authors.affiliation: American Eye Center, Mandaluyong City, Philippines.
authors.forename: Cesar Ramon G
authors.initials: CR
authors.lastname: Espiritu
authors.forename: Victor L
authors.initials: VL
authors.lastname: Caparas
authors.forename: Joanne G
authors.initials: JG
authors.lastname: Bolinao
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000187:drug effects*; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002452:Cell Count; D009877:Endophthalmitis / Q000382:microbiology / Q000517:prevention & control; D004728:Endothelium, Corneal / Q000187:drug effects / Q000473:pathology; D015817:Eye Infections / Q000382:microbiology / Q000517:prevention & control; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D018918:Phacoemulsification; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D014792:Visual Acuity
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D011804:Quinolines; D000077266:Moxifloxacin